In earlier phase two trials the company sponsored, patients taking orforglipron achieved about 14.7% weight loss, on average, almost matching Ozempic
Patient and Prescriber Choice Choice of treatment needs to be directed by both the patient and the prescriber as their needs may be slightly different
We do not yet have long-term controlled taper trials
We plan to develop a clinical-grade way to antagonize [the] GLP-1 receptor to bring it to the clinic in oncology. Paolo Fiorina, MD, PhD As the popular GLP-1 receptor agonist medications like Ozempic and Wegovy activate rather than block the GLP-1 receptor, what might this mean for those taking these drugs
The concentrate is mixed with water before consumption and is particularly suitable for integration into a training routine
Weight loss is not a one-size-fits-all journey, and what works for one person may not be suitable for another